Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

BRVE

Braveheart Bio Inc

29.74

Aug 06 • 3:15 PM ET +11.74 (65.22%)

Healthcare Biotechnology USA NASD

Today, 1:01 PMStrong IPO demand drives ~70% first-day pop for Braveheart Bio (BRVE)

Scroll to Statements

Index	-
Market Cap	-
Enterprise Value	-
Income	-
Sales	-
Book/sh	-1.11
Cash/sh	-
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	-
IPO	Aug 06, 2026

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	-
P/C	-
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	8.11
Current Ratio	8.11
Debt/Eq	0.01
LT Debt/Eq	0.00
Option/Short	No / No

EPS (ttm)	-
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	- -
Sales past 3/5Y	- -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	-
Sales Q/Q	-
Earnings	-
EPS/Sales Surpr.	- -

Insider Own	-
Insider Trans	-
Inst Own	-
Inst Trans	-
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	0.00%
SMA50	0.00%
SMA200	0.00%
Trades

Shs Outstand	70.65M
Shs Float	-
Short Float	-
Short Ratio	-
Short Interest	-
52W High	- -
52W Low	- -
Volatility	- -
ATR (14)	2.14
RSI (14)	-
Beta	-
Rel Volume	-
Avg Volume	-
Volume	2,430,814

Perf Week	-
Perf Month	-
Perf Quarter	-
Perf Half Y	-
Perf YTD	-
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	-
Target Price	-
Prev Close	18.00
Price	29.74
Change	65.22%

Braveheart Bio, Inc. engages in the development of therapeutics to treat hypertrophic cardiomyopathy. Its lead product candidate is BHB-1839 which is a small-molecule cardiac myosin inhibitor. The company was founded on May 13,2024 and is headquartered in San Francisco, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BRVE

Braveheart Bio Inc

Upgrade your Finviz experience